IN8bio Promotes Kate Rochlin to President as INB-619 Shows Complete B-Cell Depletion
IN8bio has promoted Dr. Kate Rochlin, COO since December 2021, to President and Chief Operating Officer effective immediately, positioning her to oversee operations as the company advances its γδ T cell therapy and engager pipeline. Under her leadership, preclinical INB-619 achieved complete B cell depletion with minimal cytokine release and robust γδ T cell expansion.
1. Leadership Promotion
IN8bio has elevated Kate Rochlin, Ph.D., from Chief Operating Officer to President and Chief Operating Officer, effective immediately. In her expanded role, she will continue to manage company operations and prepare for the next phase of growth across manufacturing, clinical and research teams.
2. Professional Background
Dr. Rochlin joined IN8bio in August 2020 as Associate Vice President of Operations and Innovation, was promoted to Vice President later that year, and became COO in December 2021. She brings over 17 years of experience spanning scientific research, business development, clinical manufacturing and corporate strategy in the biotech sector.
3. Pipeline and Milestones
Under Dr. Rochlin’s operational leadership, IN8bio’s preclinical INB-619 program achieved complete B cell depletion comparable to approved T cell engagers while minimizing cytokine release and expanding γδ T cells. She has overseen multiple Phase 1/2 clinical programs in glioblastoma, hematological cancers and autoimmune indications.